



ASX ANNOUNCEMENT

Starpharma Highlights of FY2016 Presentation

Melbourne, Australia; 30 August 2016: Starpharma Holdings Ltd (ASX:SPL, OTCQX:SPHRY) advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.

The interview and accompanying presentation highlights the Company's recent achievements and outlook, including the:

- Rapidly advancing DEP™ programs;
- Expansion of the Company's DEP™ partnership with AstraZeneca, in addition to its two DEP™ candidates under the existing multiproduct drug delivery license;
- Signing of two new Targeted DEP™ partnerships with world leading antibody-drug conjugate companies;
- Signing of an exclusive license and supply agreement for the VivaGel® condom in China for the Government market ;
- Product launch plans of VivaGel® BV for treatment and rapid relief of Bacterial Vaginosis (BV) symptoms; and
- Phase 3 clinical trials of VivaGel® BV for the prevention of recurrent BV which are more than 90% enrolled.

The interview will be available on Starpharma's website at www.starpharma.com

A copy of the presentation slides is attached.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has signed a license agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel® BV in Australia and New Zealand. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell's Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, Manix®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™

docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP™ drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

For more information please visit: www.starpharma.com

FOR FURTHER INFORMATION

Media:

WE Buchan:

Rebecca Wilson
Mob: +61 417 382 391
rwilson@buchanwe.com.au

Arthur Chan
+61 2 9237 2805
achan@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary

+61 3 8532 2704
investor.relations@starpharma.com
www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.



starpharma

For personal use only

Dr. Jackie Fairley CEO

STARPHARMA HOLDINGS LIMITED
ASX:SPL; OTCQX:SPHY

Financial News Network
Starpharma FY2016 Highlights

30 Aug 2016


This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

A global leader in dendrimer nanoparticles

Starpharma's portfolio - internal programs and commercial partnerships with leading companies

Starpharma's Dendrimer Platform
~120 granted patents

For internal use only



Important regulatory and commercial milestones for VivaGel® Portfolio

For personal use only

VivaGel® BV: Two attractive commercial opportunities



VivaGel® BV Treatment & Symptomatic Relief

- Acute use product
- Global market est. >US\$750M
- EU marketing approval achieved
- Regulatory processes leveraging EU approval underway in multiple regions
- License signed with Aspen for ANZ; further partnering discussions well-advanced
- 2016 launch planned; manufacture underway

VivaGel® BV Prevention of Recurrence

- Chronic use product
- Global market est. >US\$1B
- Unmet need: no approved products
- Majority of BV sufferers experience recurrence
- Phase 3 program nearing completion
- Partnering discussions ongoing
- NDA planning underway

Benefits of VivaGel® BV

- Rapid relief & resolution
- Non-antibiotic
- Not systemically absorbed
- Excellent tolerability
- Selective antimicrobial effect

Rapidly building momentum for DEP™ programs

DEP™ Drug Delivery – Dual Strategy



Internal DEP™ Programs

- Application to established drugs
- Potential for multiple products
- Self funded
- Return through licensing after early clinical development eg. DEP™ docetaxel
- Patent life extension

Partnered DEP™ Programs

- Application to partner drugs (typically proprietary)
- Platform with broad optionality
- Partner funded development
- Returns through milestones and royalties eg. AstraZeneca
- Patent life extension

Benefits of DEP™

- Improved efficacy
- Reduced toxicity
- Improved pharmacokinetics
- Improved solubility
- Patent life extension

For personal use only

Adama Licenses Priostar® for novel 2,4-D products

Priostar® Agrochemicals – Dual Strategy



Internal Priostar® Programs

- Application to established agrochemicals eg. Glyphosate
- Self funded
- Returns through licensing
- Patent life extension

Partnered Priostar® Programs

- Application to partner actives – either generic or proprietary
- Platform with broad optionality
- Partner funded development, with royalty based returns
- Adama Priostar® license for improved 2,4-D products
- Patent life extension

Benefits of Priostar®

Better in the can:

- Solubility enhancement
- Increased loading
- Formulation stability
- Reduction/removal of solvents – “greener” formulations

Better in the the field:

- Increased efficacy
- Modification of soil penetration
- Protection of actives
- Patent life extension

Starpharma Holdings – Key Financials

Strong Financial Position

Key Financial Highlights FY2016:

• **Total revenue and other income \$4.6M (+173% - includes the first US\$2M DEP™ AZ milestone)**

• **Cash Burn \$17.5M (+28%; increased due to significant clinical programs in FY2016)**

• **Net proceeds of \$32.6M from equity placement and SPP**

• **Cash at year end \$46.0M**

Key Financial Data	FY 2016 AUD \$M	FY 2015 AUD \$M
Total revenue & other income	4.6	1.7
R&D Tax Incentive	3.5	3.5
Net loss after tax	(22.7)	(19.0)
Net Cash Burn ¹	(17.5)	(13.7)
Closing Cash (30 June)	46.0	30.8

¹ Net cash burn is considered a non-IFRS value and has not been audited in accordance with Australian Accounting Standards. Net cash burn is calculated by the movement in cash and cash equivalents at 30 June of the applicable year adjusted for net proceeds on the issue of any equity

Operational Highlights



VivaGel® Portfolio

- EU marketing approval for VivaGel® BV
- Licensing deal with Aspen for VivaGel® BV (Australia and NZ)
- Phase 3 clinical trials of VivaGel® BV for the prevention of recurrent BV >90% enrolled
- License signed for the VivaGel® condom in China for the Government market
- Significant regulatory progress for the VivaGel® condom in a number of important markets
- VivaGel® active shows potent antiviral activity against Zika virus

DEP™ Drug Delivery

- Multiproduct DEP™ license with AstraZeneca with two DEP™ candidates nominated so far
- Additional DEP™ program with AstraZeneca for a new DEP™ candidate from their portfolio
- DEP™ docetaxel phase 1 trial - promising efficacy signals & no neutropenia or hair loss reported
- Impressive results for DEP™ cabazitaxel and Targeted DEP™ candidates in human cancer models
- Two new Targeted DEP™ partnerships signed with world leading antibody-drug conjugate companies


Priostar® Agrochemicals

- Adama licenses Priostar® for the US market for leading herbicide 2,4-D
- Signing of several new partnerships with leading agrochemical companies including major Japanese agrochemical business
- Important progress and field trial results for internal Priostar® agrochemical programs

Development & Expansion of AstraZeneca partnership




AstraZeneca Multiproduct DEP™ License



“SPL estimates that each product successfully commercialised under this agreement could be worth around US\$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more”

*Jackie Fairley,
Starpharma CEO
September 2015*



For personal use only

VivaGel[®] Portfolio



- Further regulatory approvals for VivaGel[®] BV for Treatment & Symptomatic Relief
- Further licenses for VivaGel[®] BV marketing (multiple territories)
- Launch of VivaGel[®] BV for Treatment & Symptomatic Relief
- Completion Phase 3 Prevention of BV Recurrence trials for VivaGel[®] BV & commercialisation
- Further approvals and geographic roll-out of the VivaGel[®] condom with multiple partners

DEP[™] Drug Delivery



- Completion of DEP[™] docetaxel Phase 1 clinical trial and commencement of Phase 2
- AZ program announcements – milestones, further compounds advanced
- Other Partnered DEP[™] deals
- Additional internal DEP[™] candidates advanced through preclinical and into the clinic

Priostar[®] Agrochemicals



- Progress with Adama 2,4-D Priostar[®] license
- Further Priostar[®] licenses and commercial arrangements and regional expansion of existing deals
- Advance internal Priostar[®] candidates eg. glyphosate and glyphosinate ammonium: regulatory-compliant field trials and pre-registration activities to support commercialisation